EUVIMEDEUVIMED entdecken
Open Access

Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals

Lei Lei, Hu Li, Xue-Kai Wang, Jian-Rui Li, Han Sun, Hong-Ying Li, Jia-Yu Li, Mei Tang, Jing-Chen Xu, Biao Dong, Yue Gong, Dan-Qing Song und 2 weitere

International Journal of Biological Sciences · 01.01.2025 · 21 (2) · 802-822

DOI: 10.7150/ijbs.103305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 01.01.2025. Verfasst von Lei Lei und 13 weiteren Autor:innen. Beteiligte Einrichtung: CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical Coll…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Antiviral Agents, Hepacivirus. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although therapies based on direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus (HCV) in patients, there is still a high risk of liver fibrosis even after a sustained virological response. Therefore, it is of great clinical importance to understand the mechanism of potential factors that promote liver fibrosis after virological cure by treatment with DAAs. Here, we found that tubulointerstitial nephritis antigen-like 1 (TINAGL1) is significantly increased in HCV-infected hepatocytes and in the liver of patients with liver fibrosis, and that higher TINAGL1 expression persists in HCV-eradicated hepatocytes after treatment with DAAs. Overexpression of TINAGL1 in the liver triggers and exacerbates liver fibrosis, and xenotransplantation of HCV-eradicated Huh7.5 cells leads to a higher risk of hepatocellular carcinoma. Conversely, knockdown of TINAGL1 expression prevents and attenuates the progression of liver fibrosis in mice. TINAGL1 binds and stabilizes platelet-derived growth factor-BB (PDGF-BB) in hepatocytes, leading to an increase in intracellular and extracellular PDGF-BB, which sensitizes the PDGF-BB/PDGFRβ pathway to activate hepatic stellate cells. This study highlights that TINAGL1 is a new factor contributing to liver fibrosis after injury, including but not limited to HCV infection, even after virological cure by DAAs, and emphasizes the therapeutic potential of TINAGL1 as an innovative target for the treatment of liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisAntiviral AgentsHepacivirusAnimalsHumansMiceHepatocytesMaleBecaplerminHepatitis CProto-Oncogene Proteins c-sis

Stichwörter der Autor:innen

DAAsHCV eradicationLiver fibrosisPDGF-BB/PDGFRβ pathwayTINAGL1

Substanzen

Antiviral AgentsBecaplerminProto-Oncogene Proteins c-sis

Autor:innen und Institutionen

  • CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
  • NHC Key Laboratory of Biotechnology for Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China.

Zitieren

APA

Lei, L., Li, H., Wang, X. K., Li, J. R., Sun, H., Li, H. Y., Li, J. Y., Tang, M., Xu, J. C., Dong, B., Gong, Y., Song, D. Q., Jiang, J. D., & Peng, Z. G. (2025). Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals. International Journal of Biological Sciences, 21(2), 802-822. https://doi.org/10.7150/ijbs.103305

Vancouver

Lei L, Li H, Wang XK, Li JR, Sun H, Li HY, et al. Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals. International Journal of Biological Sciences. 2025;21(2):802-822. doi:10.7150/ijbs.103305

BibTeX
@article{Lei2025,
  author = {Lei, Lei and Li, Hu and Wang, Xue-Kai and Li, Jian-Rui and Sun, Han and Li, Hong-Ying and Li, Jia-Yu and Tang, Mei and Xu, Jing-Chen and Dong, Biao and Gong, Yue and Song, Dan-Qing and Jiang, Jian-Dong and Peng, Zong-Gen},
  title = {Tubulointerstitial nephritis antigen-like 1 promotes the progression of liver fibrosis after HCV eradication with direct-acting antivirals},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  volume = {21},
  number = {2},
  pages = {802--822},
  doi = {10.7150/ijbs.103305}
}
Kostenlos starten →